Cypress Bioscience Inc. and its partner Forest Laboratories Inc. submitted a new drug application (NDA) for milnacipran to treat fibromyalgia, a disorder characterized by pain, fatigue, muscle stiffness, cognitive dysfunction and insomnia. (BioWorld Today)